-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGR-1505 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SGR-1505 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SGR-1505 in Mantle Cell Lymphoma Drug Details: SDGR-3 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSBR-1290 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSBR-1290 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSBR-1290 in Obesity Drug Details: GSBR-1290 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSBR-1290 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSBR-1290 in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSBR-1290 in Type 2 Diabetes Drug Details: GSBR-1290 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANPA-0073 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANPA-0073 in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANPA-0073 in Pulmonary Arterial Hypertension Drug Details: ANPA-0073 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANPA-0073 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANPA-0073 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANPA-0073 in Idiopathic Pulmonary Fibrosis Drug Details: ANPA-0073 is under...
-
Product Insights
NewFemale Contraception – Drugs In Development, 2024
Empower your strategies with our Female Contraception – Drugs In Development, 2024 report and make more profitable business decisions. Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization, and "natural" methods. Contraception generally works by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every...
-
Product Insights
NewPulmonary Arterial Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
-
Product Insights
NewPulmonary Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGR-1505 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SGR-1505 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SGR-1505 in B-Cell Non-Hodgkin Lymphoma Drug Details: SDGR-3 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGR-1505 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SGR-1505 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SGR-1505 in Diffuse Large B-Cell Lymphoma Drug Details: SDGR-3...